WO2005026132A1 - ホスホジエステラーゼのcAMP基質特異的阻害剤 - Google Patents
ホスホジエステラーゼのcAMP基質特異的阻害剤 Download PDFInfo
- Publication number
- WO2005026132A1 WO2005026132A1 PCT/JP2004/013648 JP2004013648W WO2005026132A1 WO 2005026132 A1 WO2005026132 A1 WO 2005026132A1 JP 2004013648 W JP2004013648 W JP 2004013648W WO 2005026132 A1 WO2005026132 A1 WO 2005026132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- camp
- pde
- pharmaceutically acceptable
- maleate
- benzoguanamine derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
Definitions
- the present invention provides a cAMP substrate for phosphodiesterase, comprising as an active ingredient a benzoguanamine derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof (hereinafter, referred to as the compound of the present invention). Related to specific inhibitors.
- R 1 and R 2 are the same or different and represent hydrogen or halogen.
- the compound of the present invention has excellent anti-ulcer action, cell defense action, and gastric mucosal blood flow increasing action (see, for example, Patent Documents 13 and 13, 13).
- 2,4-Diamino 6- (2,5-dichroic phenol) -1,3,5-triazine maleate (generic name: ilsogladine maleate) (hereinafter referred to as ilsogramazine maleate) It is marketed under the brand name Gaslon N as a treatment for gastric ulcers, acute gastritis and chronic gastritis.
- maleic Sani Rusogurajin are known to have increased activity of the rat gastric mucosa intracellular cAMP (e.g., Non-Patent Document 4 reference.) 0
- cAMP 3,5,1-monocyclic adenosine monophosphate
- Intracellular levels of cAMP which functions as a second messenger, are regulated by mechanisms that control synthesis and degradation.
- the synthesis of cAMP is controlled by adenylate cyclase, which is directly activated by drugs such as forskolin.
- prostaglandins such as PGE or PGI
- j8-adrenergic receptor agonists may bind to cell surface receptors.
- cAMP degradation is controlled by some phosphodiesterase (PDE) isozymes. These PDEs also control the degradation of cGMP (guanosine 3 ', 5'-cyclic monophosphate).
- PDE phosphodiesterase
- cGMP guanosine 3 ', 5'-cyclic monophosphate
- PDEs are functionally classified on the basis of their substrate specificity, enzyme activity regulation mechanism, and sensitivity of various inhibitors.
- PDE1—PDE11 11 types of PDEs
- PDE4—PDE8 are cAMP substrate-specific PDEs that hydrolyze only cAMP as a substrate.
- PDE5, PDE6 and PDE9 are cGMP-specific PDEs that hydrolyze only cGMP as a substrate.
- PDE1-PDE3, PDE10 and PDE11 are PDEs that hydrolyze both cAMP and cGMP cyclic nucleotides.
- PDE1 is regulated by calmodulin
- PDE2 and PDE3 are regulated by cGMP.
- PDE10 and PDE11 are both PDEs that hydrolyze both cAMP and cGMP cyclic nucleotides, but PDE10 is distributed very much in the brain, while PDE11 is distributed in peripheral tissues such as skeletal muscle and prostate. I do.
- PDE5, PDE6 and PDE9 are all cGMP-specific PDEs. Force PDE6 is expressed only in the retina! /, And is known as PDE! /.
- PDE4 inhibitors include bronchial asthma, including atopic asthma, chronic bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, systemic lupus erythematosus, allergic rhinitis, atopic dermatitis, conjunctivitis, urticaria, psoriasis, keloids, gingiva It can be used to treat inflammation, periodontitis, alveolar pyorrhea, scleroderma, rheumatoid arthritis, chronic glomerulonephritis, Crohn's disease, ulcerative colitis, and esophagitis.
- PDE7 is also highly expressed on T-lymphocytes (for example, see Non-Patent Document 8), its inhibitor can be used for treating T cell-dependent diseases such as rheumatoid arthritis and psoriasis.
- PDE 1 is a calmodulin-dependent PDE. Inhibitors of PDE 1 are useful as therapeutic agents for urinary incontinence (e.g., see Patent Document 9.) 0
- PDE3 is a cGMP inhibitory PDE. Increased intracellular cAMP due to PDE3 inhibition causes, for example, relaxation of vascular smooth muscle and inhibition of platelet aggregation (for example, see Non-Patent Document 10). Therefore, this inhibitor is useful as a therapeutic agent for thrombosis. It is.
- Patent Document 1 JP-A-50-111085
- Patent Document 2 Japanese Patent Application Laid-Open No. 50-111086
- Patent Document 3 JP-A-51-75083
- Non-Patent Document l Ueda F, et al, Arzneim.-Forsch./Drug Res., 34 (1), 474 (1984)
- Non-Patent Document 2 Fumio Ueda et al., Applied Pharmacology, 33 (1), 143 (1987)
- Non-Patent Document 3 Shin Hiramatsu et al., Pharmacology and Therapy, 11 (7), 2481 (1983)
- Non-Patent Document 4 Fumio Ueda et al., Applied Pharmacology, 33 (1), 157 (1987)
- Non-Patent Document 5 Francis SH, et al, Prog Nucleic Acid Res Mol Biol,
- Non-Patent Document 6 Barnes PJ, Nature, 402, B31-B38 (1999)
- Non-Patent Document 7 Mauro M, et al, Trends Pharmacol Sci, 18, 164-170 (1997)
- Non-Patent Document 8 Li L, et al, Science, 283, 848-851 (1999)
- Non-Patent Document 9 Truss MC, et al, World J Urol, 18, 439-443 (2000)
- Non-Patent Document 10 Sudo T, et al, Biochem Pharmacol, 59, 347-356 (2 000)
- Non-Patent Document 11 Banner KH, et al, Eur Respir J, 8, 996-1000 (199 5)
- Non-Patent Document 12 Mauro M, et al, Trends Pharmacol Sci, 18, 164-170 (1997)
- Non-Patent Document 13 Ministry of Health and Welfare Pharmaceutical Safety Bureau, "Pharmaceutical Safety Information Separate Volume, Summary of Side Effects of New Pharmaceuticals, etc. 1996,” October 1997, pl2
- Non-Patent Document 14 Nichols MR, et al, Mol. Pharmacol., 57, 738-45 (2000)
- Non-Patent Document 15 Oka M, et al, Naunyn Schmie debergs Arch Pharmacol, 356, 189-96 (1997)
- Non-Patent Document 16 Wang P, et al, Mol. Pharmacol., 56, 170-174 (1999)
- An object of the present invention is to provide a cAMP substrate-specific inhibitor of PDE, comprising a benzoguanamine derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present inventors have conducted extensive studies on the effect of the compound of the present invention on increasing cAMP in gastric mucosal cells, and as a result, the compound of the present invention selectively inhibits only the hydrolysis of cAMP by PDE. And completed the present invention.
- the present invention provides
- Bronchial asthma including atopic asthma, chronic bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, systemic lupus erythematosus, allergic rhinitis, atopic dermatitis containing the compound of the present invention as an active ingredient , Conjunctivitis, urticaria, psoriasis, keloid, gingivitis, periodontitis, alveolar pyorrhea, scleroderma, rheumatoid arthritis, chronic glomerulonephritis, Crohn's disease, ulcerative colitis, esophagitis, urinary incontinence or Preventive drugs for thrombosis or their treatment
- the compound of the present invention shows a strong inhibitory effect on the hydrolysis of cAMP by PDE, but has a clear effect on the hydrolysis of cGMP by PDE. No inhibitory effect.
- Test Examples 2 to 4 below they have almost the same inhibitory activity against PDE1, PDE2, PDE3 and PDE4 isozymes.
- a cAMP substrate-specific inhibitor of phosphodiesterase is a drug that selectively inhibits only the hydrolysis of cAMP by PDE and has no obvious inhibitory effect on the hydrolysis of cGMP by PDE! / ⁇ ⁇ .
- Halogen includes, for example, fluorine, chlorine, bromine and iodine.
- “Pharmaceutically acceptable salts” include, for example, salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfur Organic acid salts such as fonic acid, benzenesulfonic acid and methanesulfonic acid can be mentioned.
- FIG. 1 is a graph showing the results of examining the effect of ilsogradazine maleate on the hydrolysis of cAMP by purified PDEs derived from human brain.
- the vertical axis represents the amount of cAMP (pmol / 30 min.), And the horizontal axis represents the concentration (M) of ilsogladine maleate.
- "**" in the graph indicates the result of Dunnett's test (** P * 0.01).
- FIG. 2 is a graph showing the results of examining the effect of ilsoglazin maleate on the hydrolysis of cGMP by purified PDE derived from cereal brain.
- the vertical axis represents the amount of cGMP (pmolZ30min.), And the horizontal axis represents the concentration (M) of ilsograzin maleate.
- FIG. 3 is a graph showing the results of an investigation of the effects of various PDE inhibitors on the hydrolysis of cAMP by purified PDEs derived from human brain.
- the vertical axis indicates the amount of cAMP (pmol / 30 min.).
- "**" in the graph indicates the result of Dunnett's test (** P ⁇ 0.01).
- FIG. 4 is a graph showing the results of examining the effects of various PDE inhibitors on the hydrolysis of cAMP by purified PDE derived from the red heart.
- the vertical axis indicates the amount of cAMP (pmol / 30min.).
- "**" in the graph indicates the result of Dunnett's test (** P * 0.01).
- FIG. 6 is a graph showing the results of studies on the effects of various PDE inhibitors on human neutrophil cAMP production.
- FIG. 8 is a graph showing the results of examining the effect of ilsoglazin maleate in the presence of IBMX on cAMP production by human neutrophils.
- the vertical axis represents the amount of cAMP (pmol / 30min.).
- "**" in the graph indicates the result of Dunnett's test (** P * 0.01).
- the compound of the present invention is a known compound and can be produced by a known method (for example, see Patent Documents 11 to 13). For example, by reacting a mono- or dihalogenobenzo-tolyl with dicyandiamide, or by reacting a mono- or dihalogenobenzoic acid derivative (potassium carboxylic acid, acid halide, ester, amide, etc.) with a biguanide. Can be manufactured.
- the compound of the present invention can be used as a medicament as a free base, but can also be used in the form of a pharmaceutically acceptable salt by a known method.
- the maleate salt of the compound of the present invention can be obtained by dissolving a benzoguanamine derivative in an alcohol solution or an ethyl acetate solution in which an equivalent amount of maleic acid is dissolved, and concentrating the solution.
- the compound of the present invention is used as a pharmaceutical composition containing, for example, 0.01 to 99.5%, preferably 0.5 to 90%, as it is or in a pharmaceutically acceptable nontoxic and inert carrier. Administered to animals, including humans.
- the carrier one or more of solid, semi-solid or liquid diluents, fillers and other auxiliaries for formulation are used.
- the drug is administered in unit dosage form.
- the drug is not limited to those capable of being administered intravenously, orally, intramuscularly, topically (such as transdermally), or rectally. Needless to say, it is administered in a dosage form suitable for these administration methods.
- the dose of the PDE as a cAMP substrate-specific inhibitor is preferably determined in consideration of the nature and degree of disease 'injury, age, patient condition such as body weight, administration route, and the like.
- the amount of the active ingredient of the drug according to the present invention for an adult is generally in the range of 0.1 to 10 OOmgZ human, preferably in the range of 500mg / human per day.
- lower doses may be sufficient, and conversely, higher doses may be required. It can also be administered in 2-4 divided doses a day.
- solid or liquid dosage units for example, powders, powders, tablets, dragees, capsules, granules, suspensions, solutions, syrups, drops, sublingual tablets and other agents This can be done by type.
- Powders are produced by making the drug into a suitable fineness. Powders are prepared by comminuting the drug to a suitable fineness and then admixing it with a pharmaceutical carrier, such as starch, edible carbohydrates such as mannitol, and the like. If necessary, flavoring agents, preservatives, dispersing agents, coloring agents, flavors and the like may be added.
- a pharmaceutical carrier such as starch, edible carbohydrates such as mannitol, and the like.
- flavoring agents, preservatives, dispersing agents, coloring agents, flavors and the like may be added.
- a capsule is prepared by first filling a powdered powder, a powder or a granule as described in the section of a tablet as described above into a capsule shell such as a gelatin capsule. It is manufactured by Lubricants and glidants, such as colloidal silica, talc, magnesium stearate, calcium stearate, and solid polyethylene glycol, are mixed with the powdered state, and then the filling operation is performed. You can do it too.
- Capsules were ingested by adding disintegrants and solubilizers such as carboxymethylcellulose, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxymethyl starch sodium, calcium carbonate, and sodium carbonate. Sometimes the efficacy of the drug can be improved.
- a fine powder of a drug can be suspended and dispersed in vegetable oil, polyethylene glycol, glycerin, and a surfactant, and this can be wrapped in a gelatin sheet to form a soft capsule.
- Tablets are made by adding an excipient, forming a powder mixture, granulating or slugging, adding a disintegrant or lubricant and compressing.
- the powder mixture is prepared by mixing the appropriately powdered drug with the diluent or base described above and, if necessary, a binder (eg, sodium carboxymethinoresenorelose, methinoresenorelose, hydroxypropinolemethinoresenole).
- the powder mixture can be moistened with a binder such as syrup, starch paste, gum arabic, cellulose solution or polymer solution, stirred and mixed, dried and ground to give granules.
- a binder such as syrup, starch paste, gum arabic, cellulose solution or polymer solution, stirred and mixed, dried and ground to give granules.
- the granules thus produced can be prevented from adhering to each other by adding stearic acid, stearic acid salt, talc, mineral oil or the like as a lubricant.
- the lubricated mixture is then compressed with tablets.
- the uncoated tablets thus produced can be coated with a film or coated with sugar.
- the drug may be directly tableted after being mixed with a fluid inactive carrier that does not undergo the granulating and sluging steps as described above.
- Transparent or translucent protective coatings consisting of a hermetic shell coating, coatings of sugar or polymeric materials, and polish coatings made of wax may also be used.
- compositions such as solutions, syrups, elixirs and the like can also be presented in dosage unit form so that a given quantity contains a fixed amount of the drug.
- Syrups are prepared by dissolving the drug in an appropriate flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic carrier.
- Suspensions are formulated by dispersing the drug in a non-toxic carrier.
- Solubilizers and emulsifiers eg, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters
- preservatives eg, peppermint oil, saccharin
- flavoring agents eg, peppermint oil, saccharin
- dosage unit formulations for oral administration may be microencapsulated.
- the formulation can also provide an extended period of action or sustained release by coating or embedding in a polymer 'wax or the like.
- Administration into tissues can be performed by using a liquid dosage unit form for subcutaneous, intramuscular or intravenous injection, for example, a solution or suspension. These are produced by suspending or dissolving a fixed amount of the drug in a non-toxic liquid carrier suitable for the purpose of injection, such as an aqueous or oily medium, and then sterilizing the suspension or solution. You. Non-toxic salts or salt solutions may be added to make the injection solution isotonic. More stable Agents, preservatives and emulsifiers can be used in combination.
- a drug is used to dissolve or dissolve a drug in water having a low melting point, such as polyethylene dalicol, cocoa butter, semi-synthetic fat (eg, Vitebsol®), higher esters (eg, palmitic acid).
- a low melting point such as polyethylene dalicol, cocoa butter, semi-synthetic fat (eg, Vitebsol®), higher esters (eg, palmitic acid).
- Myristyl ester and a suppository produced by dissolving or suspending them in a mixture thereof.
- Test Example 1 The effect of ilsoglazin maleate on purified PDE derived from pea brain
- PDE (Sigma-RBI, Natick, Mass., USA) purified from the brain of the rat was subjected to a Krebs-Ringer bicarbonate solution (120 mM NaCl, 3.3 mM KC1, 1 mM) in the presence of cAMP or cGMP and ilsogladine maleate. 3 mM CaCl, 1.2 mM MgSO,
- KRB solution ucose, pH 7.4
- perchloric acid final concentration 0.2 M
- the reaction solution was centrifuged at 10,000 X g for 15 minutes (4 ° C), and the supernatant was used for quantification of cAMP and cGMP.
- the supernatant is neutralized by adding KCO, and 10,000 xg for 15 minutes (4
- Test Example 1 The PDE used in Test Example 1 was incubated in the KRB solution for 30 minutes (37 ° C.) in the presence of cAMP and each test drug. The reaction was stopped by exothermic perchloric acid (final concentration 0.2 M). The reaction solution was centrifuged at 10,000 X g for 15 minutes (4 ° C), and the supernatant was used for cAMP quantification. The supernatant is neutralized by adding K CO and 10,000 X g
- PDE 1 is a selective inhibitor vinpocetine (5 X 10- 5 M), a PD E2 selective inhibitors Erisuro 9-1 (2-hydroxy-3-Noel) adenine hydrochloride ( EH NA) (5 X 10- 5 M), and a PDE4 selective inhibitor rolipram (5 X 10- 5 M) is partially suppressed the hydrolysis of cAMP by any ⁇ shea brain-derived purified PDE did.
- PDE3 selective inhibitors cilostamide (5 X 10- 5 M) are ⁇ shea NoYukari come mosquitoes such effect on cAMP hydrolysis by purified PDE ⁇ ivy.
- Test Example 3 Discussion on the effect of ilsoglazin maleate on purified PDE derived from red heart The same examination as in Test Example 1 and Test Example 2 was carried out using purified PDE derived from the oak heart instead of the purified PDE derived from the oak brain.
- reaction solution was centrifuged at 10,000 X g for 15 minutes (4 ° C), and the supernatant was used for cAMP quantification.
- the supernatant was neutralized by adding KCO, and
- cAMP was quantified using an EIA kit. The results are shown in Fig. 4 (Effects of various PDE selective inhibitors on the hydrolysis of ScAMP) and Fig. 5 (Effects of illsogladine maleate on the hydrolysis of ScAMP).
- PDE 1 is a selective inhibitor vinpocetine (5 X 10- 5 M), ⁇ Beauty, a is cilostamide (5 X 10- 5 M) is PDE3 selective inhibitors, both The effect of the combined use of vinpocetine and cilostamide was additive, partially inhibiting the hydrolysis of cAMP by purified PDEs from ⁇ ⁇ heart.
- PDE2 selective inhibitors EHNA (5 X 10- 5 M)
- a PDE4 selective inhibitor rolipram (5 X 10- 5 M) are of cAMP by ⁇ shea heart from purified PDE hydrolyzed Had no effect on It is a non-selective PDE inhibitor IBMX (10- 3 M) was completely inhibited hydrolysis by PDE.
- Irusogurajin maleic acid PDE 1 was selective inhibitors and it Binpo Sechin presence (5 X 10- 5 M) the hydrolysis of cAMP by PDE depending on the concentration in the suppression. Further, Irusogurajin maleate, even for cAMP hydrolysis by PDE in the presence Shirosuta bromide is PDE3 selective inhibitors (5 X 10- 5 M), it showed a concentration-dependent inhibitory effect.
- Neutrophils were collected from vein blood of healthy subjects. After heparinized blood was diluted with physiological saline, the blood was layered on a blood cell separating agent (Polymorphprep, AXIS-Shield PoCAS, Oslo, Norway), and neutrophils were separated and collected according to the manual attached to the blood separating agent. The collected neutrophils were adjusted to a predetermined concentration with Hank's balanced salt solution (HBSS). The cAMP content was measured according to a known method (for example, see Non-Patent Document 15). 0 Separated neutrophils (1 ⁇ 10 6 per assav) were washed with HBSS, and then washed at 37 ° C. CO
- cAMP quantification was performed using an EIA kit. The results are shown in Fig. 6 (effects of various PDE selective inhibitors), Fig. 7 (effects of illsogladine maleate), and Fig. 8 (effects of illsogladine maleate and non-selective PDE inhibitors).
- cAMP amount is PDE4 selective inhibitor rolipram - reacted with (5 X 10 5 M), or a non-selective PDE inhibitor IBMX (10- 3 M) was increased when the, PDE 1 is a selective inhibitor vinpocetine (5 X 10- 5 M), PDE2 are selective iNHIBITOR EHNA (5 X 10- 5 M) , or PDE3 is a selective inhibitor when cilostamide the (5 X 10- 5 M) were allowed to act respectively, the increase in cAMP amount it has failed observed.
- ilsograzin maleate increased AMP production of neutrophils in a concentration-dependent manner, and the effect was statistically significant at concentrations of 10-'M or more.
- PDE4 is mainly responsible for cAMP hydrolysis in human neutrophils. This result is consistent with the report that PDE4B is highly expressed in human neutrophils (for example, see Non-Patent Document 16). In addition, it is clear that ilsograzin maleate exhibits an inhibitory effect on at least PDE4.
- the mixed powder in this ratio is tablet-formed by an ordinary method to give an internal tablet.
- the mixed powder in this ratio is tablet-formed by an ordinary method to give an internal tablet.
- the compound of the present invention selectively inhibits only the hydrolysis of cAMP by PDE and has no clear inhibitory effect on the hydrolysis of cGMP by PDE.
- Asthma chronic bronchitis, chronic obstructive pulmonary disease, adult dyspnea syndrome, systemic lupus erythematosus, allergic rhinitis, atopic dermatitis, conjunctivitis, hives Rash, psoriasis, keloid, gingivitis, periodontitis, alveolar pyorrhea, scleroderma, rheumatoid arthritis, chronic glomerulonephritis, Crohn's disease, ulcerative colitis, esophagitis, urinary incontinence or thrombosis Or it is useful as a therapeutic agent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005513980A JPWO2005026132A1 (ja) | 2003-09-17 | 2004-09-17 | ホスホジエステラーゼのcAMP基質特異的阻害剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-323810 | 2003-09-17 | ||
JP2003323810 | 2003-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005026132A1 true WO2005026132A1 (ja) | 2005-03-24 |
Family
ID=34308696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013648 WO2005026132A1 (ja) | 2003-09-17 | 2004-09-17 | ホスホジエステラーゼのcAMP基質特異的阻害剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005026132A1 (ja) |
WO (1) | WO2005026132A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118170A1 (ja) * | 2005-04-27 | 2006-11-09 | Teika Pharmaceutical Co., Ltd. | 角膜疾患治療剤 |
CN100438874C (zh) * | 2005-12-16 | 2008-12-03 | 浙江工业大学 | 一种马来酸依索拉啶胃滞留片 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011247A1 (en) * | 1990-12-20 | 1992-07-09 | Nippon Shinyaku Co., Ltd. | Anticancer composition and compound |
JPH04300832A (ja) * | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
WO1996032945A1 (fr) * | 1995-04-20 | 1996-10-24 | Nippon Shinyaku Co., Ltd. | Inhibiteur de neovascularisation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5855423A (ja) * | 1981-09-25 | 1983-04-01 | Nippon Shinyaku Co Ltd | ベンゾグアナミン類を主成分としする医薬 |
WO1991001733A1 (en) * | 1989-08-09 | 1991-02-21 | Nippon Shinyaku Co., Ltd. | Remedy |
US6313156B1 (en) * | 1999-12-23 | 2001-11-06 | Icos Corporation | Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors |
US6348602B1 (en) * | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
GB0203193D0 (en) * | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
-
2004
- 2004-09-17 JP JP2005513980A patent/JPWO2005026132A1/ja active Pending
- 2004-09-17 WO PCT/JP2004/013648 patent/WO2005026132A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011247A1 (en) * | 1990-12-20 | 1992-07-09 | Nippon Shinyaku Co., Ltd. | Anticancer composition and compound |
JPH04300832A (ja) * | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
WO1996032945A1 (fr) * | 1995-04-20 | 1996-10-24 | Nippon Shinyaku Co., Ltd. | Inhibiteur de neovascularisation |
Non-Patent Citations (1)
Title |
---|
VANDERHOEK R. ET AL.: "Bis(dimethylamino)-s-triazinyl antiinflammatory agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 11, 1973, pages 1305 - 1306, XP002086950 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118170A1 (ja) * | 2005-04-27 | 2006-11-09 | Teika Pharmaceutical Co., Ltd. | 角膜疾患治療剤 |
US8268824B2 (en) | 2005-04-27 | 2012-09-18 | Teika Pharmaceutical Co., Ltd. | Therapeutic agent for corneal disease |
CN100438874C (zh) * | 2005-12-16 | 2008-12-03 | 浙江工业大学 | 一种马来酸依索拉啶胃滞留片 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005026132A1 (ja) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
JP2016104723A (ja) | 有機化合物 | |
HU226057B1 (en) | N6 heterocyclic substituted adenosine derivatives, their use for production of pharmaceutical compositions and pharmaceutical compositions containing them | |
US20090220621A1 (en) | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination | |
JP2008546786A (ja) | Pde5インヒビターの迅速吸収性経口処方物 | |
EP1455791A1 (en) | Method for administering birb 796 bs | |
WO2007093624A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
TW200522981A (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
CN100423723C (zh) | 多发性硬化症的治疗剂 | |
US20140018430A1 (en) | Novel composition for the treatment of cystic fibrosis | |
CA3059775A1 (en) | Methods of treating developmental encephalopathies | |
DE102005016345A1 (de) | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten | |
AU775591B2 (en) | Anxiety method | |
TWI248362B (en) | A pharmaceutical composition for the prevention of migraine recurrence | |
WO2005026132A1 (ja) | ホスホジエステラーゼのcAMP基質特異的阻害剤 | |
EP2474544B1 (en) | Therapeutic agent for anxiety disorders | |
JP2003277265A (ja) | eNOS発現に起因する疾患の予防または治療薬 | |
RU2690685C2 (ru) | Фармацевтические композиции, содержащие алпелисиб | |
KR100740079B1 (ko) | 당뇨병성 신경 장해용 의약 조성물 | |
EP3856185A1 (en) | Balipodect for treating or preventing autism spectrum disorders | |
EP1353624A2 (en) | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination | |
EP3241562A1 (en) | Zonisamide for use in the treatment of breast cancer | |
CA2670517A1 (en) | Medicament with controlled release containing galanthamine | |
US20080009623A1 (en) | Pyrimidine compounds | |
CA2946270A1 (en) | Drug for treatment of tinnitus patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513980 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |